The global glaucoma eye drops market is expected to grow at a CAGR of 4.5% during the forecast period, to reach USD 1.6 billion by 2030. The growth of this market can be attributed to the increasing prevalence of glaucoma and its associated risk factors such as age, family history, and race. The global glaucoma eye drops market is segmented on the basis of type into prostaglandin analogs, beta blockers, alpha agonists, carbonic anhydrase inhibitors (CAIs), and rho kinase inhibitors; on the basis of application into hospital pharmacies and optical shops; and on the basis of region into North America, Latin America, Europe, Asia Pacific (APAC), Middle East & Africa (MEA).
- Glaucoma is a chronic eye disease that can lead to blindness if left untreated.
- The global population is aging, which will increase the number of people with glaucoma and other age-related eye diseases.
- The prevalence of glaucoma in the United States has increased from 2% in the 1970s to 3% in 2010, and it is expected to rise to 4% by 2020 due to an aging population and increasing rates of diabetes mellitus, hypertension, and obesity among Americans.
- Glaucoma treatments are expensive; therefore, many patients do not receive treatment until they have lost significant vision or are at risk for blindness because they cannot afford treatment or lack access to care providers who can prescribe these treatments on a regular basis.
- There are no cures for glaucoma; however, there are several types of medications that can help control symptoms such as pain or pressure in the eyes (ocular hypertension) caused by high fluid pressure inside the eye (intraocular pressure).
Industry Growth Insights published a new data on “Glaucoma Eye Drops Market”. The research report is titled “Glaucoma Eye Drops Market research by Types (Prostaglandin Analogs, Beta Blockers, Alpha Agonists, Carbonic Anhydrase Inhibitors (CAIs), Rho Khinase Inhibitors), By Applications (Hospital Pharmacies, Optical Shop, Online Stores, Others), By Players/Companies Novartis, Allergan, Mylan, Bausch + Lomb”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Glaucoma Eye Drops Market Research Report
By Type
Prostaglandin Analogs, Beta Blockers, Alpha Agonists, Carbonic Anhydrase Inhibitors (CAIs), Rho Khinase Inhibitors
By Application
Hospital Pharmacies, Optical Shop, Online Stores, Others
By Companies
Novartis, Allergan, Mylan, Bausch + Lomb
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
239
Number of Tables & Figures
168
Customization Available
Yes, the report can be customized as per your need.
Global Glaucoma Eye Drops Market Report Segments:
The global Glaucoma Eye Drops market is segmented on the basis of:
Types
Prostaglandin Analogs, Beta Blockers, Alpha Agonists, Carbonic Anhydrase Inhibitors (CAIs), Rho Khinase Inhibitors
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital Pharmacies, Optical Shop, Online Stores, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Novartis
- Allergan
- Mylan
- Bausch + Lomb
Highlights of The Glaucoma Eye Drops Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Prostaglandin Analogs
- Beta Blockers
- Alpha Agonists
- Carbonic Anhydrase Inhibitors (CAIs)
- Rho Khinase Inhibitors
- By Application:
- Hospital Pharmacies
- Optical Shop
- Online Stores
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Glaucoma Eye Drops Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Glaucoma eye drops are a type of medication used to lower the pressure in the eyes. This can help to prevent blindness from glaucoma.
Some of the major players in the glaucoma eye drops market are Novartis, Allergan, Mylan, Bausch + Lomb.
The glaucoma eye drops market is expected to grow at a compound annual growth rate of 4.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Glaucoma Eye Drops Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Glaucoma Eye Drops Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Glaucoma Eye Drops Market - Supply Chain
4.5. Global Glaucoma Eye Drops Market Forecast
4.5.1. Glaucoma Eye Drops Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Glaucoma Eye Drops Market Size (000 Units) and Y-o-Y Growth
4.5.3. Glaucoma Eye Drops Market Absolute $ Opportunity
5. Global Glaucoma Eye Drops Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Glaucoma Eye Drops Market Size and Volume Forecast by Type
5.3.1. Prostaglandin Analogs
5.3.2. Beta Blockers
5.3.3. Alpha Agonists
5.3.4. Carbonic Anhydrase Inhibitors (CAIs)
5.3.5. Rho Khinase Inhibitors
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Glaucoma Eye Drops Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Glaucoma Eye Drops Market Size and Volume Forecast by Application
6.3.1. Hospital Pharmacies
6.3.2. Optical Shop
6.3.3. Online Stores
6.3.4. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Glaucoma Eye Drops Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Glaucoma Eye Drops Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Glaucoma Eye Drops Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Glaucoma Eye Drops Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Glaucoma Eye Drops Demand Share Forecast, 2019-2026
9. North America Glaucoma Eye Drops Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Glaucoma Eye Drops Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Glaucoma Eye Drops Market Size and Volume Forecast by Application
9.4.1. Hospital Pharmacies
9.4.2. Optical Shop
9.4.3. Online Stores
9.4.4. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Glaucoma Eye Drops Market Size and Volume Forecast by Type
9.7.1. Prostaglandin Analogs
9.7.2. Beta Blockers
9.7.3. Alpha Agonists
9.7.4. Carbonic Anhydrase Inhibitors (CAIs)
9.7.5. Rho Khinase Inhibitors
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Glaucoma Eye Drops Demand Share Forecast, 2019-2026
10. Latin America Glaucoma Eye Drops Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Glaucoma Eye Drops Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Glaucoma Eye Drops Market Size and Volume Forecast by Application
10.4.1. Hospital Pharmacies
10.4.2. Optical Shop
10.4.3. Online Stores
10.4.4. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Glaucoma Eye Drops Market Size and Volume Forecast by Type
10.7.1. Prostaglandin Analogs
10.7.2. Beta Blockers
10.7.3. Alpha Agonists
10.7.4. Carbonic Anhydrase Inhibitors (CAIs)
10.7.5. Rho Khinase Inhibitors
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Glaucoma Eye Drops Demand Share Forecast, 2019-2026
11. Europe Glaucoma Eye Drops Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Glaucoma Eye Drops Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Glaucoma Eye Drops Market Size and Volume Forecast by Application
11.4.1. Hospital Pharmacies
11.4.2. Optical Shop
11.4.3. Online Stores
11.4.4. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Glaucoma Eye Drops Market Size and Volume Forecast by Type
11.7.1. Prostaglandin Analogs
11.7.2. Beta Blockers
11.7.3. Alpha Agonists
11.7.4. Carbonic Anhydrase Inhibitors (CAIs)
11.7.5. Rho Khinase Inhibitors
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Glaucoma Eye Drops Demand Share, 2019-2026
12. Asia Pacific Glaucoma Eye Drops Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Glaucoma Eye Drops Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Glaucoma Eye Drops Market Size and Volume Forecast by Application
12.4.1. Hospital Pharmacies
12.4.2. Optical Shop
12.4.3. Online Stores
12.4.4. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Glaucoma Eye Drops Market Size and Volume Forecast by Type
12.7.1. Prostaglandin Analogs
12.7.2. Beta Blockers
12.7.3. Alpha Agonists
12.7.4. Carbonic Anhydrase Inhibitors (CAIs)
12.7.5. Rho Khinase Inhibitors
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Glaucoma Eye Drops Demand Share, 2019-2026
13. Middle East & Africa Glaucoma Eye Drops Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Glaucoma Eye Drops Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Glaucoma Eye Drops Market Size and Volume Forecast by Application
13.4.1. Hospital Pharmacies
13.4.2. Optical Shop
13.4.3. Online Stores
13.4.4. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Glaucoma Eye Drops Market Size and Volume Forecast by Type
13.7.1. Prostaglandin Analogs
13.7.2. Beta Blockers
13.7.3. Alpha Agonists
13.7.4. Carbonic Anhydrase Inhibitors (CAIs)
13.7.5. Rho Khinase Inhibitors
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Glaucoma Eye Drops Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Glaucoma Eye Drops Market: Market Share Analysis
14.2. Glaucoma Eye Drops Distributors and Customers
14.3. Glaucoma Eye Drops Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Novartis
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Allergan
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Mylan
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Bausch + Lomb
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. COMPANY5
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. COMPANY6
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. COMPANY7
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook